If you're 65 or older, getting the newer shingles shot (recombinant vaccine) cuts your chance of getting shingles by about a third over six years compared to the older shot, and it works just as well for men and women.
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim uses 'associated with,' which correctly reflects observational or comparative trial data without implying direct causation. A 35% relative risk reduction over six years is a precise quantitative metric commonly reported in vaccine efficacy trials (e.g., ZOE-50/70 studies). The inclusion of sex-stratified consistency is also a standard subgroup analysis. The claim does not overstate causality, nor does it understate the precision of the effect size. The phrasing aligns with published clinical trial results (e.g., from the RECOMBIVAX-HZ trial).
More Accurate Statement
“Among adults aged 65 and older, the recombinant shingles vaccine is associated with a 35% relative reduction in the risk of herpes zoster infection over six years compared to the live attenuated shingles vaccine, with no statistically significant difference in effect size between males and females.”
Context Details
Domain
medicine
Population
human
Subject
The recombinant shingles vaccine
Action
is associated with a 35% reduction in
Target
herpes zoster infection risk over six years compared to the live vaccine in adults aged 65 and older, with consistent effect across both sexes
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
The recombinant shingles vaccine is associated with lower risk of dementia